United States was United Therapeutics’s largest region in fiscal 2024, bringing in $1.03B of $1.11B (93%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $600.70M | $708.60M | $731.10M | $1.03B | ||||||||||||
| Revenues | — | — | — | — | ||||||||||||
| Revenue From External Customers | — | — | — | — | ||||||||||||
| Net Revenues To External Customers | — | — | — | — | ||||||||||||
| Rest-Of-World | $90.30M | $92.70M | $80.20M | $73.90M | ||||||||||||
| Total | $691.00M | $801.30M | $811.30M | $1.11B |
United Therapeutics brought in $1.11B from its two regions in fiscal 2024, the year ended December 31, 2024. That was up 36.5% from $811.30M in fiscal 2023. United States was the largest at $1.03B (93.3%), ahead of Rest-Of-World at $73.90M (6.7%).
Compared with fiscal 2023, United States grew 41.3% to $1.03B, while Rest-Of-World fell 7.9% to $73.90M. From fiscal 2021 to 2024, combined revenue from these regions grew from $691.00M to $1.11B, a compound annual growth rate of 17.0%. United States' share of the total rose from 86.9% to 93.3%.
Nebulized Tyvaso was United Therapeutics’s largest product and service line in fiscal 2021, bringing in $600.70M of $2.16B (28%).
| Product and Service | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nebulized Tyvaso | — | — | — | $600.70M | |||||||||
| Remodulin | $599.00M | $587.00M | $516.70M | $423.40M | |||||||||
| Salesrevenuegoodsnet | — | — | — | — | |||||||||
| Sales Revenue, Goods, Net | — | — | — | — | |||||||||
| Net Product Sales | — | — | — | — | |||||||||
| Tyvaso | $415.20M | $415.60M | $483.30M | $600.70M | |||||||||
| Orenitram | $205.10M | $225.30M | $293.10M | $306.10M | |||||||||
| Adcirca | $323.70M | $107.20M | $67.30M | $55.90M | |||||||||
| Unituxin | $84.80M | $113.70M | $122.90M | $178.10M | |||||||||
| Total | $1.63B | $1.45B | $1.48B | $2.16B |
United Therapeutics brought in $2.16B from its six product and service lines in fiscal 2021, the year ended December 31, 2021. United Therapeutics regrouped these lines after fiscal 2020, so the total does not compare directly with that year's $1.48B. Nebulized Tyvaso was the largest at $600.70M (27.7%), ahead of Tyvaso at $600.70M (27.7%) and Remodulin at $423.40M (19.6%). The other three lines brought in $540.10M combined.
Compared with fiscal 2020, Unituxin grew fastest, up 44.9% to $178.10M, while Remodulin fell the most, down 18.1% to $423.40M.
United Therapeutics began breaking out Nebulized Tyvaso in fiscal 2021, when it brought in $600.70M.
United Therapeutics (UTHR) reports its revenue by geography and by product and service. In fiscal 2024, United States was its largest region, bringing in $1.03B (93.3% of the total), followed by Rest-Of-World at $73.90M (6.7%).
United States was United Therapeutics' largest region in fiscal 2024, bringing in $1.03B, or 93.3% of the $1.11B total across its two regions.
Nebulized Tyvaso was United Therapeutics' largest product and service line in fiscal 2021, bringing in $600.70M, or 27.7% of the $2.16B total across its six product and service lines.
United States grew faster than Rest-Of-World in fiscal 2024, up 41.3% from $731.10M to $1.03B. Rest-Of-World fell 7.9% to $73.90M.
Every figure comes from United Therapeutics' annual financial filings, as reported. Each line keeps the name United Therapeutics gives it, and years follow its fiscal calendar.
United Therapeutics' revenue by geography goes back to fiscal 2009, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.